Compare Adaptive Biotechnologies Corp (ADPT) vs Blackrock Inc (BLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Blackrock Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while Blackrock Inc trades at $1,148.43 (market cap $177.92B). The key difference: Blackrock Inc is far larger — about 44× Adaptive Biotechnologies Corp's market cap, and Blackrock Inc pays a 2% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | BLK | |
|---|---|---|
Market Cap | $4.04B | $177.92B |
Sector | Health | Financials |
52-Week High | $25.45 | $1.20K |
52-Week Low | $12.30 | $922.90 |
Enterprise Value | $4.10B | $179.02B |
Volume | — | 641,547 |
Dividend Yield | — | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
BLK trades at $1,131.40, down slightly by 0.44% today, with a bullish technical signal from moving averages and strong analyst support. The company reported revenue of $24.22 billion for 2025, with net income of $5.55 billion, and has consistently beaten EPS estimates in recent quarters. Recent news highlights BlackRock's involvement in a major AI financing initiative with Nvidia and other firms.
The outlook remains positive given strong earnings performance and a consensus buy rating from analysts, with a price target of $1,350. Key risks include potential legal challenges from investor lawsuits and volatile cash flow trends, but institutional confidence and strategic partnerships provide a solid foundation for growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Blackrock Inc
BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.
Read more on BLK →
